Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Solid Biosciences Inc.NASDAQ: SLDB

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $239.03M rose 26.0% year over year, ahead of the +18.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 4547.6% from the prior quarter. Over 3 fiscal years it compounded at +37.5% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.0% holds above the trailing-twelve-month pace of +18.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$239.03M+4547.6% QoQ
Last fiscal yearDec 2025
$194.45M+58.8% YoY
LTMMar 2026
$243.75M+18.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.0%——
1 year+58.8%——
3-year CAGR+37.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
194.45M USD
Year-over-year change
+58.8%
4-year CAGR
+9.6%

Financing Cash Flow vs competitors

How SLDB compares with its peers on the latest reported figures

  • SLDB's LTM Mar 2026 financing cash flow of $243.75M is the 4th largest of the 10 companies compared; the peer median is $109.5M.
  • Its year-over-year change of +18.9% is the 6th highest of 10, against a peer median of +66.3%.
  • Over three fiscal years its annual growth of +37.5% compares with a peer median of +20.1%.
SLDB Competitors Peer median
Financing Cash Flow for SLDB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYNDyne Therapeutics, Inc.LTM Jun 2026$713.47M +170.6%+187.7%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$536M +2312.8%+25.4%53.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$250.31M +66.3%+271.0%—
SLDBSolid Biosciences Inc.LTM Mar 2026$243.75M +18.9%+37.5%—
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$180.57M -256.8%—8.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$124.44M +575.7%+232.1%141.0%
PEPGPepGen Inc.LTM Mar 2026$109.5M +6044.6%-1.3%—
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$34.21M -82.5%+14.8%—
NGNENeurogene Inc.LTM Mar 2026$30.68M -83.9%-23.0%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$446K -99.2%-49.5%0.6%
Peer median (excluding SLDB) $109.5M+66.3%+20.1%30.7%

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Depreciation & Amortization2.96M2.41M2.58M2.46M(1.87M)
Deferred Income Tax1.21M0000
Stock-Based Compensation13.37M7.54M7.63M10.52M16.91M
Change in Working Capital(23.04M)(3.69M)(6.34M)2.85M(6.82M)
Accounts Receivables(110K)110K000
Inventory(11.5M)0000
Accounts Payables1.21M(5.25M)(764K)2.21M(1.09M)
Other Working Capital(12.64M)1.45M(5.57M)645K(5.73M)
Other Non-Cash Items(81K)(18.25M)(2.03M)8.86M9.82M
Operating Cash Flow(77.76M)(97.98M)(94.18M)(100.01M)(156.29M)
Capital Expenditures(1.28M)(3.02M)(1.52M)(654K)(1.15M)
Acquisitions (Net)89.81M31.52M05K85K
Purchases of Investments(141.25M)(182.76M)(117.43M)(204.34M)(235.89M)
Sales of Investments51.44M212.81M128.63M188.9M178.5M
Other Investing Activities(89.81M)600K000
Investing Cash Flow(91.09M)59.16M9.69M(16.09M)(58.45M)
Debt Repayment02.08M0(473K)(723K)
Common Stock Issued134.88M72.55M2.97M127.23M194.74M
Common Stock Repurchased000(5.11M)0
Dividends Paid00000
Other Financing Activities107K203K148K794K425K
Financing Cash Flow134.99M74.83M3.12M122.44M194.45M
Effect of Forex Changes00000
Net Change in Cash(33.87M)36.01M(81.37M)6.34M(20.3M)
Free Cash Flow(79.05M)(100.99M)(95.7M)(100.67M)(157.44M)

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.